Diagnose sepsis with more certainty in about one hour

SeptiCyte® RAPID addresses the unmet need for a rapid, sensitive, and reliable diagnostic test to provide physicians with actionable results to rule out sepsis with high confidence, or to expedite preventative action with prompt therapeutic interventions.

SeptiCyte® cartridges are formatted to work with the Biocartis IdyllaTM platform, a fully automated, RT- PCR based molecular testing system designed to offer fast and easy access to molecular biomarker information. Its compact scalable design and outstanding ease of use allows it to be used in virtually any laboratory setting.

For more information about the IdyllaTM solution please visit biocartis.com.

Introducing SeptiCyte® RAPID
A revolutionary way to diagnose sepsis

Rule in/out sepsis

  • Measures host response to systemic infection by PCR
  • mRNA signature from blood
  • High NPV and high PPV to differentiate sepsis vs. SIRS

Actionable results in about 1 hour

  • 1 step sample to result
  • Rapid assay turnaround time

Ease of use

  • Fully automated sample to result process
  • All reagents integrated in single-use cartridge
  • 2-minute hands-on time

Result as probability risk score (SeptiScore®)

  • Result interpretation via 4 probability bands
  • The SeptiScore® correlates with sepsis risk

Increased laboratory service level

  • Minimize need for additional diagnostic tests
  • Early sepsis rule out to obviate pathogen ID tests
Email us to learn more about SeptiCyte® RAPID, a lab test for sepsis, on the IdyllaTM Platform

SeptiCyte® RAPID cartridge for IdyllaTM

SeptiCyte® RAPID Workflow on the IdyllaTM Platform

SeptiCyte® RAPID is designed for ease of use and rapid, accurate results in about an hour.

Learn more about SeptiCyte® RAPID lab test for sepsis on the IdyllaTM Platform

SeptiCyte® RAPID provides the technology to radically accelerate treatment decisions by providing rapid, accurate diagnosis of sepsis. SeptiCyte® RAPID and the IdyllaTM Platform allow for a user-friendly, fully-automated system to test for sepsis.

SeptiCyte® RAPID is a CE-marked IVD within the EU and and has 510(k) clearance in the US. Immunexpress is using the Idylla trademark under license from Biocartis.

This product contains SuperScript™ III Reverse Transcriptase and is provided subject to a license under patents or patent applications owned by or licensed to Life Technologies Corporation, which license is limited to the human diagnostic field and research field and specifically excludes applications in forensics (including human identity testing). The SuperScript™ III trademark is owned by Life Technologies Corporation.